- Imugene (IMU) has received approval from the U.S. Food and Drug Administration (FDA) to begin a clinical trial for its PD1-Vaxx drug
- Then the company gained Investigational New Drug (IND) approval to begin enrolment in a phase one trial in patients with non-small cell lung cancer
- The primary aim of the phase one study is to determine the safety and optimal dosage of the drug, as well as measuring efficacy and immune response
- PD1-Vaxx is already in phase one clinical trials in Australia
- Imugene also cashed up and ready to progress PD1-Vaxx and three other immunotherapies through clinical trials in the current quarter
- Imugene is trading grey for 5.6 cents
